Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. Co.'s products include Trokendi XR and Oxtellar XR, which are the once-daily extended release topiramate and oxcarbazepine products indicated for the treatment of epilepsy; APOKYN, which is a product indicated for the intermittent treatment of hypomobility or off episodes in patients with Parkinson's Disease (PD); XADAGO, which is an once-daily product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD; and MYOBLOC, which is a product indicated for the treatment of cervical dystonia and sialorrhea in adults. We show 48 historical shares outstanding datapoints in our SUPN shares outstanding history coverage, used to compute SUPN market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing SUPN market cap history over the course of time is important for investors
interested in comparing SUPN's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of SUPN versus a peer is one thing; comparing
SUPN market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like SUPN can fluctuate over the course of history.
With this page we aim to empower investors researching SUPN by allowing them to research the SUPN market cap history. |
Free SUPN Email Alerts:
Video: The Importance of Market Cap
